{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T23:45:14Z","timestamp":1792107914647,"version":"4.4.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s00467-026-07452-x","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T18:21:49Z","timestamp":1783448509000},"page":"4501-4511","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Vancomycin exposure in critically ill children undergoing high intensity continuous renal replacement therapy"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-5644-2689","authenticated-orcid":false,"given":"Victor","family":"Belliard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naim","family":"Bouazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baptiste","family":"Grenier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilde","family":"Grapin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Nivet-Antoine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"No\u00e9mie","family":"de Cacqueray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marc","family":"Treluyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Berthaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Renolleau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Oualha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9751-8249","authenticated-orcid":false,"given":"Agathe","family":"B\u00e9ranger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"key":"7452_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2011.04.010","author":"W Chaijamorn","year":"2011","unstructured":"Chaijamorn W, Jitsurong A, Wiwattanawongsa K, Wanakamanee U, Dandecha P (2011) Vancomycin clearance during continuous venovenous haemofiltration in critically ill patients. Int J Antimicrob Agents. https:\/\/doi.org\/10.1016\/j.ijantimicag.2011.04.010","journal-title":"Int J Antimicrob Agents"},{"key":"7452_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00134-002-1495-z","volume":"28","author":"S Uchino","year":"2002","unstructured":"Uchino S, Cole L, Morimatsu H, Goldsmith D, Bellomo R (2002) Clearance of vancomycin during high-volume haemofiltration: impact of pre-dilution. Intensive Care Med 28:11","journal-title":"Intensive Care Med"},{"key":"7452_CR3","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1Q488","author":"CA Paciullo","year":"2013","unstructured":"Paciullo CA, Harned KC, Davis GA, Connor MJ, Winstead PS (2013) Vancomycin clearance in high-volume venovenous hemofiltration. Ann Pharmacother. https:\/\/doi.org\/10.1345\/aph.1Q488","journal-title":"Ann Pharmacother"},{"key":"7452_CR4","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1128\/AAC.05609-11","volume":"56","author":"J Brown","year":"2012","unstructured":"Brown J, Brown K, Forrest A (2012) Vancomycin AUC 24 \/MIC ratio in patients with complicated bacteremia and infective endocarditis due to methicillin-resistant Staphylococcus aureus and its association with attributable mortality during hospitalization. Antimicrob Agents Chemother 56:634\u2013638. https:\/\/doi.org\/10.1128\/AAC.05609-11","journal-title":"Antimicrob Agents Chemother"},{"key":"7452_CR5","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1007\/s40262-021-01027-9","volume":"60","author":"E Chung","year":"2021","unstructured":"Chung E, Sen J, Patel P, Seto W (2021) Population pharmacokinetic models of vancomycin in paediatric patients: a systematic review. Clin Pharmacokinet 60:985\u20131001. https:\/\/doi.org\/10.1007\/s40262-021-01027-9","journal-title":"Clin Pharmacokinet"},{"key":"7452_CR6","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","volume":"77","author":"MJ Rybak","year":"2020","unstructured":"Rybak MJ, Le J, Lodise TP, Levine DP, Bradley JS, Liu C et al (2020) Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 77:835\u2013864. https:\/\/doi.org\/10.1093\/ajhp\/zxaa036","journal-title":"Am J Health Syst Pharm"},{"key":"7452_CR7","doi-asserted-by":"publisher","DOI":"10.1097\/PCC.0000000000000656","author":"JJ Cies","year":"2016","unstructured":"Cies JJ, Moore WS, Conley SB, Muneeruddin S, Parker J, Shea P et al (2016) Continuous infusion vancomycin through the addition of vancomycin to the continuous renal replacement therapy solution in the PICU: a case series*. Pediatr Crit Care Med. https:\/\/doi.org\/10.1097\/PCC.0000000000000656","journal-title":"Pediatr Crit Care Med"},{"key":"7452_CR8","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1097\/INF.0b013e318299f75c","volume":"32","author":"A Frymoyer","year":"2013","unstructured":"Frymoyer A, Guglielmo BJ, Hersh AL (2013) Desired vancomycin trough serum concentration for treating invasive methicillin-resistant staphylococcal infections. Pediatr Infect Dis J 32:1077\u20131079. https:\/\/doi.org\/10.1097\/INF.0b013e318299f75c","journal-title":"Pediatr Infect Dis J"},{"key":"7452_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2014.03.009","author":"L Escobar","year":"2014","unstructured":"Escobar L, Andresen M, Downey P, Gai MN, Regueira T, B\u00f3rquez T et al (2014) Population pharmacokinetics and dose simulation of vancomycin in critically ill patients during high-volume haemofiltration. Int J Antimicrob Agents. https:\/\/doi.org\/10.1016\/j.ijantimicag.2014.03.009","journal-title":"Int J Antimicrob Agents"},{"key":"7452_CR10","doi-asserted-by":"publisher","first-page":"82","DOI":"10.2146\/ajhp080434","volume":"66","author":"M Rybak","year":"2009","unstructured":"Rybak M, Lomaestro B, Rotschafer JC, Moellering R, Craig W, Billeter M et al (2009) Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 66:82\u201398. https:\/\/doi.org\/10.2146\/ajhp080434","journal-title":"Am J Health Syst Pharm"},{"key":"7452_CR11","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.1128\/AAC.01708-10","volume":"55","author":"JA Roberts","year":"2011","unstructured":"Roberts JA, Taccone FS, Udy AA, Vincent JL, Jacobs F, Lipman J (2011) Vancomycin dosing in critically ill patients: robust methods for improved continuous-infusion regimens. Antimicrob Agents Chemother 55:2704\u20132709. https:\/\/doi.org\/10.1128\/AAC.01708-10","journal-title":"Antimicrob Agents Chemother"},{"key":"7452_CR12","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1186\/s12879-026-12560-y","volume":"26","author":"Y Wu","year":"2026","unstructured":"Wu Y, Liu S, Shi C, Zhang M, Chen J, Huang X et al (2026) Continuous versus intermittent vancomycin infusions in critically ill children with gram-positive bacterial infections: a randomized controlled trial. BMC Infect Dis 26:410. https:\/\/doi.org\/10.1186\/s12879-026-12560-y","journal-title":"BMC Infect Dis"},{"issue":"1","key":"7452_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13613-015-0048-x","volume":"5","author":"H Lin","year":"2015","unstructured":"Lin H, Bukovskaya Y, De Moya M, Lee J, Schmidt U (2015) Vancomycin continuous infusion versus intermittent infusion during continuous venovenous hemofiltration: slow and steady may win the race. Ann Intensive Care 5(1):1. https:\/\/doi.org\/10.1186\/s13613-015-0048-x","journal-title":"Ann Intensive Care"},{"key":"7452_CR14","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt261","author":"M Beumier","year":"2013","unstructured":"Beumier M, Roberts JA, Kabtouri H, Hites M, Cotton F, Wolff F et al (2013) A new regimen for continuous infusion of vancomycin during continuous renal replacement therapy. J Antimicrob Chemother. https:\/\/doi.org\/10.1093\/jac\/dkt261","journal-title":"J Antimicrob Chemother"},{"key":"7452_CR15","doi-asserted-by":"publisher","first-page":"65","DOI":"10.5507\/bp.2012.092","volume":"158","author":"N Petejova","year":"2014","unstructured":"Petejova N, Martinek A, Zahalkova J, Duricova J, Brozmannova H, Urbanek K et al (2014) Vancomycin pharmacokinetics during high-volume continuous venovenous hemofiltration in critically ill septic patients. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 158:65\u201372. https:\/\/doi.org\/10.5507\/bp.2012.092","journal-title":"Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub"},{"key":"7452_CR16","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.ijantimicag.2014.06.002","volume":"44","author":"W Chaijamorn","year":"2014","unstructured":"Chaijamorn W, Wanakamanee U (2014) Pharmacokinetics of vancomycin in critically ill patients undergoing continuous venovenous haemodialysis. Int J Antimicrob Agents 44:4. https:\/\/doi.org\/10.1016\/j.ijantimicag.2014.06.002","journal-title":"Int J Antimicrob Agents"},{"key":"7452_CR17","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.ijantimicag.2013.01.018","volume":"41","author":"AA Udy","year":"2013","unstructured":"Udy AA, Covajes C, Taccone FS, Jacobs F, Vincent JL, Lipman J et al (2013) Can population pharmacokinetic modelling guide vancomycin dosing during continuous renal replacement therapy in critically ill patients? Int J Antimicrob Agents 41:6. https:\/\/doi.org\/10.1016\/j.ijantimicag.2013.01.018","journal-title":"Int J Antimicrob Agents"},{"key":"7452_CR18","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1128\/AAC.32.6.848","volume":"32","author":"KA Rodvold","year":"1988","unstructured":"Rodvold KA, Blum RA, Fischer JH, Zokufa HZ, Rotschafer JC, Crossley KB et al (1988) Vancomycin pharmacokinetics in patients with various degrees of renal function. Antimicrob Agents Chemother 32:848\u2013852. https:\/\/doi.org\/10.1128\/AAC.32.6.848","journal-title":"Antimicrob Agents Chemother"},{"key":"7452_CR19","doi-asserted-by":"publisher","first-page":"143","DOI":"10.5863\/1551-6776-28.2.143","volume":"28","author":"ML Vestal","year":"2023","unstructured":"Vestal ML, Liu B, Heath TS (2023) Evaluation of dosing regimens of vancomycin and aminoglycosides in pediatric patients on continuous renal replacement therapy. J Pediatr Pharmacol Ther 28:143\u2013148. https:\/\/doi.org\/10.5863\/1551-6776-28.2.143","journal-title":"J Pediatr Pharmacol Ther"},{"key":"7452_CR20","first-page":"3","volume":"63","author":"LM van de Vijsel","year":"2010","unstructured":"van de Vijsel LM, Walker SA, Walker SE, Yamashita S, Simor A, Hladunewich M (2010) Initial vancomycin dosing recommendations for critically ill patients undergoing continuous venovenous hemodialysis. Can J Hosp Pharm 63:3","journal-title":"Can J Hosp Pharm"},{"key":"7452_CR21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2004.02143.x","author":"ME DelDot","year":"2004","unstructured":"DelDot ME, Lipman J, Tett SE (2004) Vancomycin pharmacokinetics in critically ill patients receiving continuous venovenous haemodiafiltration. Br J Clin Pharmacol. https:\/\/doi.org\/10.1111\/j.1365-2125.2004.02143.x","journal-title":"Br J Clin Pharmacol"},{"key":"7452_CR22","doi-asserted-by":"publisher","DOI":"10.5414\/CN106993","author":"FP Wilson","year":"2012","unstructured":"Wilson FP, Berns JS (2012) Vancomycin levels are frequently subtherapeutic during continuous venovenous hemodialysis (CVVHD). Clin Nephrol 77:329\u2013331. https:\/\/doi.org\/10.5414\/CN106993","journal-title":"Clin Nephrol"},{"key":"7452_CR23","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1007\/s00228-019-02664-7","volume":"75","author":"BS Moffett","year":"2019","unstructured":"Moffett BS, Morris J, Munoz F, Arikan AA (2019) Population pharmacokinetic analysis of vancomycin in pediatric continuous renal replacement therapy. Eur J Clin Pharmacol 75:1089\u20131097. https:\/\/doi.org\/10.1007\/s00228-019-02664-7","journal-title":"Eur J Clin Pharmacol"},{"key":"7452_CR24","doi-asserted-by":"publisher","first-page":"e0199158","DOI":"10.1371\/journal.pone.0199158","volume":"13","author":"B Lee","year":"2018","unstructured":"Lee B, Kim SJ, Park JD, Park J, Jung AH, Jung SH et al (2018) Factors affecting serum concentration of vancomycin in critically ill oliguric pediatric patients receiving continuous venovenous hemodiafiltration. PLoS One 13:e0199158. https:\/\/doi.org\/10.1371\/journal.pone.0199158","journal-title":"PLoS ONE"},{"key":"7452_CR25","doi-asserted-by":"publisher","unstructured":"Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE (2003) Developmental pharmacology \u2014 drug disposition, action, and therapy in infants and children. Wood AJJ, editor. N Engl J Med 349:1157\u20131167. https:\/\/doi.org\/10.1056\/NEJMra035092","DOI":"10.1056\/NEJMra035092"},{"key":"7452_CR26","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s001340051018","volume":"25","author":"FTJ Boereboom","year":"1999","unstructured":"Boereboom FTJ, Ververs FFT, Blankestijn PJ, Savelkoul TJF, Van Dijk A (1999) Vancomycin clearance during continuous venovenous haemofiltration in critically ill patients. Intensive Care Med 25:10","journal-title":"Intensive Care Med"},{"key":"7452_CR27","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1128\/AAC.00459-12","volume":"56","author":"EN Frazee","year":"2012","unstructured":"Frazee EN, Kuper PJ, Schramm GE, Larson SL, Kashani KB, Osmon DR et al (2012) Effect of continuous venovenous hemofiltration dose on achievement of adequate vancomycin trough concentrations. Antimicrob Agents Chemother 56:12. https:\/\/doi.org\/10.1128\/AAC.00459-12","journal-title":"Antimicrob Agents Chemother"},{"key":"7452_CR28","first-page":"585","volume":"29","author":"I Park","year":"2010","unstructured":"Park I, Jang EJ, Kim H (2010) Vancomycin pharmacokinetics in oliguric patients undergoing continuous venovenous hemodialysis and continuous venovenous hemodiafiltration. Korean J Nephrol 29:585\u2013592","journal-title":"Korean J Nephrol"},{"key":"7452_CR29","doi-asserted-by":"publisher","first-page":"e01377","DOI":"10.1128\/AAC.01377-21","volume":"66","author":"V Cheng","year":"2022","unstructured":"Cheng V, Abdul-Aziz MH, Burrows F, Buscher H, Cho YJ, Corley A et al (2022) Population pharmacokinetics of vancomycin in critically ill adult patients receiving extracorporeal membrane oxygenation (an ASAP ECMO study). Antimicrob Agents Chemother 66:e01377-21. https:\/\/doi.org\/10.1128\/AAC.01377-21","journal-title":"Antimicrob Agents Chemother"},{"key":"7452_CR30","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1097\/01.PCC.0000149131.72248.E6","volume":"6","author":"B Goldstein","year":"2005","unstructured":"Goldstein B, Giroir B, Randolph A (2005) International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics*. Pediatr Crit Care Med 6:2\u20138. https:\/\/doi.org\/10.1097\/01.PCC.0000149131.72248.E6","journal-title":"Pediatr Crit Care Med"},{"key":"7452_CR31","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1097\/CCM.0b013e31828a2bbd","volume":"41","author":"S Leteurtre","year":"2013","unstructured":"Leteurtre S, Duhamel A, Salleron J, Grandbastien B, Lacroix J, Leclerc F (2013) PELOD-2: an update of the PEdiatric logistic organ dysfunction score. Crit Care Med 41:1761\u20131773. https:\/\/doi.org\/10.1097\/CCM.0b013e31828a2bbd","journal-title":"Crit Care Med"},{"key":"7452_CR32","unstructured":"anx_139384_en.pdf [Internet]. [cited 2024 Aug 19]. Available from: https:\/\/ec.europa.eu\/health\/documents\/community-register\/2017\/20170921139384\/anx_139384_en.pdf"},{"key":"7452_CR33","first-page":"1","volume":"2","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group","year":"2012","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group (2012) KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl 2:1\u2013138","journal-title":"Kidney Int Suppl"},{"key":"7452_CR34","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13054-015-0818-8","volume":"19","author":"DM Roberts","year":"2015","unstructured":"Roberts DM, Liu X, Roberts JA, Nair P, Cole L, Roberts MS et al (2015) A multicenter study on the effect of continuous hemodiafiltration intensity on antibiotic pharmacokinetics. Crit Care 19:84. https:\/\/doi.org\/10.1186\/s13054-015-0818-8","journal-title":"Crit Care"},{"key":"7452_CR35","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1097\/CCM.0000000000000317","volume":"42","author":"JA Jamal","year":"2014","unstructured":"Jamal JA, Udy AA, Lipman J, Roberts JA (2014) The impact of variation in renal replacement therapy settings on piperacillin, meropenem, and vancomycin drug clearance in the critically ill: an analysis of published literature and dosing regimens*. Crit Care Med 42:1640\u20131650. https:\/\/doi.org\/10.1097\/CCM.0000000000000317","journal-title":"Crit Care Med"},{"key":"7452_CR36","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1053\/ajkd.1998.v31.pm9631848","volume":"31","author":"M Joy","year":"1998","unstructured":"Joy M, Matzke G, Frye R, Palevsky P (1998) Determinants of vancomycin clearance by continuous venovenous hemofiltration and continuous venovenous hemodialysis. Am J Kidney Dis 31:1019\u20131027. https:\/\/doi.org\/10.1053\/ajkd.1998.v31.pm9631848","journal-title":"Am J Kidney Dis"},{"key":"7452_CR37","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1097\/CCM.0b013e318241e553","volume":"40","author":"DM Roberts","year":"2012","unstructured":"Roberts DM, Roberts JA, Roberts MS, Liu X, Nair P, Cole L et al (2012) Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study*. Crit Care Med 40:1523\u20131528. https:\/\/doi.org\/10.1097\/CCM.0b013e318241e553","journal-title":"Crit Care Med"},{"key":"7452_CR38","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1177\/106002801104501001","volume":"45","author":"C Aubron","year":"2011","unstructured":"Aubron C, Corallo CE, Nunn MO, Dooley MJ, Cheng AC (2011) Evaluation of the accuracy of a pharmacokinetic dosing program in predicting serum vancomycin concentrations in critically ill patients. Ann Pharmacother 45:1193\u20131198. https:\/\/doi.org\/10.1177\/106002801104501001","journal-title":"Ann Pharmacother"},{"key":"7452_CR39","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1097\/CCM.0b013e3181961bff","volume":"37","author":"JA Roberts","year":"2009","unstructured":"Roberts JA, Lipman J (2009) Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 37:840\u2013851. https:\/\/doi.org\/10.1097\/CCM.0b013e3181961bff","journal-title":"Crit Care Med"},{"key":"7452_CR40","doi-asserted-by":"publisher","first-page":"107005","DOI":"10.1016\/j.ijantimicag.2023.107005","volume":"62","author":"K Viertel","year":"2023","unstructured":"Viertel K, Feles E, Schulte M, Annecke T, Mattner F (2023) Serum concentration of continuously administered vancomycin influences efficacy and safety in critically ill adults: a systematic review. Int J Antimicrob Agents 62:107005. https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.107005","journal-title":"Int J Antimicrob Agents"},{"key":"7452_CR41","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/S2352-4642(25)00385-2","volume":"10","author":"PA De Cock","year":"2026","unstructured":"De Cock PA, Colman R, Smits A, Piersigilli F, Renard M, Van Damme A et al (2026) Bedside model-informed precision dosing of vancomycin in severely ill neonates and children in Belgium (the BENEFICIAL trial): a multicentre, randomised controlled trial. Lancet Child Adolesc Health 10:406\u2013417. https:\/\/doi.org\/10.1016\/S2352-4642(25)00385-2","journal-title":"Lancet Child Adolesc Health"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-026-07452-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-026-07452-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-026-07452-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T22:54:21Z","timestamp":1792104861000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-026-07452-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":41,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["7452"],"URL":"https:\/\/doi.org\/10.1007\/s00467-026-07452-x","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,7]]},"assertion":[{"value":"3 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}